These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19539578)

  • 21. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
    Wong G; Howard K; Webster A; Chapman JR; Craig JC
    Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
    de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
    Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.
    Dee A; Howell F
    Eur J Public Health; 2010 Apr; 20(2):213-9. PubMed ID: 19864366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
    Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
    Goldie SJ; Kim JJ; Kobus K; Goldhaber-Fiebert JD; Salomon J; O'shea MK; Xavier Bosch F; de Sanjosé S; Franco EL
    Vaccine; 2007 Aug; 25(33):6257-70. PubMed ID: 17606315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mathematical models of cervical cancer prevention in Latin America and the Caribbean.
    Goldie SJ; Diaz M; Constenla D; Alvis N; Andrus JK; Kim SY
    Vaccine; 2008 Aug; 26 Suppl 11():L59-72. PubMed ID: 18945403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
    Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
    Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses.
    Westra TA; Rozenbaum MH; Rogoza RM; Nijman HW; Daemen T; Postma MJ; Wilschut JC
    J Infect Dis; 2011 Aug; 204(3):377-84. PubMed ID: 21742836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
    Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
    Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
    Stanley M
    Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
    Setiawan D; Luttjeboer J; Westra TA; Wilschut JC; Suwantika AA; Daemen T; Atthobari J; Wilffert B; Postma MJ
    Expert Rev Vaccines; 2015 Apr; 14(4):589-604. PubMed ID: 25482311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ; Kobus KE; Diaz M; O'Shea M; Van Minh H; Goldie SJ
    Vaccine; 2008 Jul; 26(32):4015-24. PubMed ID: 18602731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-utility analysis of vaccination against HPV in Israel.
    Ginsberg GM; Fisher M; Ben-Shahar I; Bornstein J
    Vaccine; 2007 Sep; 25(37-38):6677-91. PubMed ID: 17706844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ; O'Shea M; Diaz M; Kim SY
    Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-benefit analysis on the HPV vaccine in Medicaid-enrolled females of the Appalachian region of Kentucky.
    Prasad SR; Hill R
    J Ky Med Assoc; 2008 Jun; 106(6):271-6. PubMed ID: 18630037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria.
    Zechmeister I; Blasio BF; Garnett G; Neilson AR; Siebert U
    Vaccine; 2009 Aug; 27(37):5133-41. PubMed ID: 19567244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrating human papillomavirus vaccination in cervical cancer control programmes.
    Franco EL; Coutlée F; Ferenczy A
    Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Developments in HPV vaccination].
    de Melker H; Kenter G; van Rossum T; Conyn-van Spaendonck M
    Ned Tijdschr Geneeskd; 2012; 156(47):A5410. PubMed ID: 23171565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.